Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert R Conley

Showing results (31-40 of 113) with videos related to

Pageof 12
Sort By:
The Journal of Clinical Psychiatry|September 18, 2009
Overestimating the prevalence of subtherapeutic dosing of atypical antipsychoticsMichael D Stensland, Haya Ascher-Svanum, Anthony H Lawson, et al.
Psychiatric Services (Washington, D.C.)|March 5, 2005
Comparison of clozapine use in Maryland and in Victoria, AustraliaRobert R Conley, Deanna L Kelly, Tim J Lambert, et al.
Clinical Neuropharmacology|December 4, 2003
Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidoneMatthew W Nelson, Rhonda R Reynolds, Deanna L Kelly, et al.
IRB|February 2, 2008
Maintaining informed consent validity during lengthy research protocolsKristen J Prentice, Paul S Appelbaum, Robert R Conley, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 22, 2011
Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophreniaXiaomei Peng, Haya Ascher-Svanum, Douglas Faries, et al.
Archives of General Psychiatry|July 9, 2004
Decreased catalytic activity and expression of protein kinase C isozymes in teenage suicide victims: a postmortem brain studyGhanshyam N Pandey, Yogesh Dwivedi, Hooriyah S Rizavi, et al.
Comprehensive Psychiatry|April 20, 2010
Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophreniaDeanna L Kelly, Stephanie Feldman, Douglas L Boggs, et al.
Journal of Psychiatric Research|September 24, 2004
Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of deathDeanna L Kelly, Joo-Cheol Shim, Stephanie M Feldman, et al.
The Journal of Clinical Psychiatry|November 25, 2003
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapineDeanna L Kelly, Julie Kreyenbuhl, Raymond C Love, et al.
Journal of Clinical Psychopharmacology|November 25, 2010
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trialsVicki P Hoffmann, Michael Case, Virginia L Stauffer, et al.
Pageof 12

Showing results (31-40 of 113) with videos related to

Sort By:
Pageof 12
The Journal of Clinical Psychiatry|September 18, 2009
Overestimating the prevalence of subtherapeutic dosing of atypical antipsychoticsMichael D Stensland, Haya Ascher-Svanum, Anthony H Lawson, et al.
Psychiatric Services (Washington, D.C.)|March 5, 2005
Comparison of clozapine use in Maryland and in Victoria, AustraliaRobert R Conley, Deanna L Kelly, Tim J Lambert, et al.
Clinical Neuropharmacology|December 4, 2003
Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidoneMatthew W Nelson, Rhonda R Reynolds, Deanna L Kelly, et al.
IRB|February 2, 2008
Maintaining informed consent validity during lengthy research protocolsKristen J Prentice, Paul S Appelbaum, Robert R Conley, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 22, 2011
Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophreniaXiaomei Peng, Haya Ascher-Svanum, Douglas Faries, et al.
Archives of General Psychiatry|July 9, 2004
Decreased catalytic activity and expression of protein kinase C isozymes in teenage suicide victims: a postmortem brain studyGhanshyam N Pandey, Yogesh Dwivedi, Hooriyah S Rizavi, et al.
Comprehensive Psychiatry|April 20, 2010
Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophreniaDeanna L Kelly, Stephanie Feldman, Douglas L Boggs, et al.
Journal of Psychiatric Research|September 24, 2004
Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of deathDeanna L Kelly, Joo-Cheol Shim, Stephanie M Feldman, et al.
The Journal of Clinical Psychiatry|November 25, 2003
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapineDeanna L Kelly, Julie Kreyenbuhl, Raymond C Love, et al.
Journal of Clinical Psychopharmacology|November 25, 2010
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trialsVicki P Hoffmann, Michael Case, Virginia L Stauffer, et al.
Pageof 12